Reimbursement basics and tips on coding, coverage and payment
Global Market Access Strategy 2026: Navigating the intersection of clinical evidence and economic value is now a universal requirement. Whether you are addressing **US Payer coverage** requirements or **European G-DRG and GHS shortcuts**, success depends on early synchronization of your clinical and reimbursement roadmaps. The resources below provide strategic guidance for medical device, biomed and diagnostic companies navigating coding, coverage, and payment across major healthcare markets.
As leading medical device reimbursement consultants, our insights bridge the gap between early clinical testing and global commercial success. These resources provide specialized medtech reimbursement consulting frameworks to help startups align regulatory tracks with payer expectations.
How to develop a winning Medical Device Reimbursement Strategy — Align clinical trial endpoints with payer economic evidence to avoid sequential data collection and prevent commercial insolvency.
Navigating the Biomed Market Access Pathway — Strategy for mitigating high-risk financial uncertainty and volatile coverage decisions in biomed commercialization.
The Crucial Role of Clarifying Your Decision Maker – A guide to identifying the stakeholders who actually control the budget in the US healthcare system.
An executive guide to Medical Device Reimbursement Strategy – Core frameworks for aligning a reimbursement strategy with the requirements of healthcare payers.
Why startups require specialized Medical Device Reimbursement Consulting – Understanding why regulatory clearance (510k/CE) is only half the battle for true market access.
5 Tips for International Medical Device Reimbursement — Essential considerations for harmonizing global clinical data to meet diverse regional payer requirements.
Breaking Common Reimbursement Myths – Debunking the most frequent misconceptions that stall MedTech commercialization.
Overcoming Medical Device Commercialization Barriers — Avoiding the common trap of focusing entirely on regulatory approval while neglecting long-term insurance payment sustainability.
Accelerated Evidence Generation in MedTech Reimbursement — Utilizing efficient, phased validation methodologies to streamline clinical data collection and accelerate market access.
Reimbursement DOs and DON’Ts – Essential strategic tips for medical device startups and established firms alike.
Reimbursement by Distributors (PDF) — Evaluating the pros and cons of delegating reimbursement responsibilities to local distribution partners.
Reimbursement pathways vary significantly by country, requiring market-specific expertise and local payer insight.
Mastering the new CMS RAPID Coverage Pathway - A strategic guide for medical device startups looking to align regulatory endpoints and secure immediate payer coverage for their technology.
The 2026 Strategy Guide to RPM and RTM Reimbursement Guide for MedTech Leaders.
Germany Market Access & Strategy
France Market Access & Strategy
Success requires identifying the specific stakeholder who controls the budget. In the US, this often shifts between the clinical department, the hospital Value Analysis Committee (VAC), and the private payer’s medical director, depending on the site of service.
Strategic synchronization means generating clinical evidence that satisfies both the FDA/CE safety requirements and the payer's demand for economic value. Waiting until after regulatory clearance to plan for reimbursement often leads to a "coverage gap."
The NUB (Neue Untersuchungs- und Behandlungsmethoden) process allows hospitals to apply for additional funding for innovative devices not yet covered by the standard G-DRG system, providing a faster route to market for new technologies.
The Liste en Sus is an "add-on" list in France that allows specific, high-cost innovative medical devices to be reimbursed separately from the standard hospital GHS (Groupes Homogènes de Séjours) rates.
Securing coverage and coding is the most critical step of your commercialization timeline. Our team maps global reimbursement pathways directly to your business goals.
